Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

PEMF Therapy

PEMF · Pulsed Magnetic Fields

Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.

40 human trials, about 300 studies, Knee-OA review (Tong 2022): 11 RCTs, 614 patients; PhysioStim nonunion trial: 139 subjects. The written rationale for this grade is still being prepared.

FDA
FDA cleared/approved ONLY for narrow uses: bone-growth stimulators for fracture nonunion (Class III PMA, 1979) and as a lumbar spinal-fusion adjunct; ActiPatch 510(k)-cleared 2017 for knee OA and plantar fasciitis. Consumer wellness mats (HealthyLine, Bemer) are at most FDA-listed, which is NOT clearance and certifies no efficacy.
WADA
Not a WADA prohibited substance or method; PEMF and electromagnetic recovery devices are not banned in or out of competition.

Reference only. Not medical advice.

What can go wrong

PEMF is generally well tolerated, with reported side effects that are minor and transient, such as skin redness. There is one absolute safety rule: do not apply an active PEMF device over a pacemaker, defibrillator, cochlear implant, deep-brain stimulator, or an intrathecal or insulin pump, because the field can interfere with or shut off the implant. Some newer implants are shielded, so anyone with an active implant should confirm with their own clinician first. Safety in pregnancy has not been established, so it is generally avoided, and caution is advised with active cancer, a seizure history, and organ-transplant immunosuppression. Wellness-mat marketing that promises detox, immune boosting or circulation benefits runs ahead of the evidence, and PEMF should not replace medical treatment for a diagnosed condition. Because sensitive situations such as pregnancy, mental-health symptoms, active malignancy and a fracture that is not healing all carry real stakes, decisions about any PEMF device belong with a qualified healthcare provider rather than a product seller.

PEMF sends low-frequency magnetic pulses through tissue, which induce tiny electrical currents. The name covers two very different things. The narrow one is a regulated medical device: non-invasive bone-growth stimulators cleared by the FDA in 1979 for fractures that will not knit, and later used as an adjunct to spinal fusion. Orthofix reports that its PhysioStim and SpinalStim systems help stubborn bones heal, and clinical series describe healing in most treated nonunions. The broad one is a large consumer wellness market of mats and wands sold for pain, recovery, circulation, sleep and energy, and that is where the evidence gets thin. For osteoarthritis the picture is genuinely mixed: a 2022 meta-analysis of 11 trials found improvement in pain, stiffness and function, but its studies were extremely heterogeneous and mostly high risk of bias, while an earlier review and the 2001 Cochrane assessment found no clinical benefit for knee-OA pain. The one review focused specifically on whole-body PEMF devices concluded the evidence is insufficient. PEMF is often confused with treatments it is not: it is not the FDA-cleared depression therapy (that is transcranial magnetic stimulation), and it is not the glioblastoma device Optune (that uses alternating electric fields). Consumer mats advertising detox or immune benefits are typically only FDA-listed, a paperwork status that says nothing about whether they work.

Real clearances for stubborn fractures and spinal fusion; the glowing wellness mat is a different, weakly-supported product

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Adjunctive treatment of established fracture nonunions with prescription bone-growth stimulators (Orthofix reports healing in most treated cases)
  • Adjunct to lumbar spinal fusion in patients at higher risk of failed fusion
  • OTC adjunct for knee-osteoarthritis and plantar-fasciitis pain (BioElectronics ActiPatch), later cleared for musculoskeletal pain generally
  • Palliative reduction of post-operative pain and edema in superficial soft tissue (SofPulse)
  • Consumer and wellness use for recovery, circulation and sleep via whole-body mats and wands, which is marketed widely but supported by insufficient controlled evidence

What people get wrong

  • Often saidPEMF mats are clinically proven to heal and detox the whole body.

    ActuallyThe only PEMF products with FDA authorization for a medical claim are prescription bone-growth stimulators (nonunion, spinal fusion) and specific pain devices such as the ActiPatch patch and SofPulse. The systematic review focused on whole-body PEMF devices (Hug and Roosli 2012) concluded the evidence for them is insufficient, and detox claims are unsupported. Consumer mats are typically only FDA-listed, which certifies nothing about efficacy.

  • Often saidPEMF is an FDA-approved treatment for depression.

    ActuallyIt is not. The magnetic device cleared for major depression is transcranial magnetic stimulation, marketed as NeuroStar, which is a different and better-evidenced technology. PEMF wellness devices are sometimes marketed near this space, but they do not carry a depression clearance.

  • Often saidPEMF reliably relieves knee-arthritis pain.

    ActuallyThe evidence is mixed rather than settled. Tong et al. 2022 pooled 11 RCTs and found benefit, but statistical heterogeneity was 93 to 99 percent and most trials were high risk of bias and lasted only 1 to 3 weeks. McCarthy et al. 2006 and the 2001 Cochrane assessment found no clinically significant benefit for knee-OA pain.

  • Often saidOptune and PEMF are the same electromagnetic cancer therapy.

    ActuallyThey are different. Optune, used for glioblastoma, delivers low-intensity alternating electric fields (tumor-treating fields) that interfere with cancer-cell division. That is a separate technology from pulsed magnetic-field devices, even though marketing sometimes blurs them.

Who profits, and who pushes back

  • Christopher McCarthy, Michael Callaghan and Jacqueline Oldham

    Pushes backAuthors, BMC Musculoskeletal Disorders systematic review of PEMF for knee OA (2006)

    There appears to be clear evidence for the recommendation that PEMF does not significantly reduce the pain of knee osteoarthritis.

  • Anke Hug and Martin Roosli

    Pushes backAuthors, Bioelectromagnetics systematic review of whole-body PEMF devices (2012)

    Neither the therapeutic efficacy nor the potential health hazards of these whole-body devices have been systematically evaluated, and independent confirmation of the sporadic positive findings is lacking.

  • Orthofix and bone-growth device makers

    Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.

    Promotes itManufacturer

    Sell FDA-approved PhysioStim and SpinalStim stimulators; cite their own nonunion and fusion data.

  • HealthyLine, Bemer, MagnaWave

    Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.

    Promotes itConsumer PEMF mat brands

    Commercial wellness sellers; broad health claims, mostly FDA-listed not approved.

  • William Pawluk, MD

    Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.

    Promotes itPEMF physician-advocate

    Author and product reseller; useful on contraindications but commercially interested.

  • Orthopedic surgeons using fusion adjuncts

    Promotes itClinicians

    Prescribe stimulators for at-risk fusion patients based on peer-reviewed data.

Where the research comes from

Share of published research by country of origin.
PlaceShare of published research
North America40%
Europe27%
Asia26%
Other7%

Research published from: USA, China, Italy, Turkey, UK.

How we got here

The story begins with physics, not marketing. Nineteenth-century work on electromagnetic induction (Faraday) set the stage, and around the turn of the century figures such as Jacques-Arsene d'Arsonval in France and Nikola Tesla experimented with applying high-frequency currents to the body. The decisive modern step came from Japan: in 1957 Eiichi Fukada and Iwao Yasuda reported the piezoelectric effect of bone in the Journal of the Physical Society of Japan, showing that mechanically stressed bone generates electrical signals, which suggested that electrical cues help direct bone growth. Building on this, Andrew Bassett, Arthur Pilla and Robert Pawluk at Columbia translated the idea into externally applied pulsed fields, publishing canine bone-repair results in Science in 1974. The FDA cleared non-invasive bone-growth stimulators for nonunion in 1979, and use widened to spinal-fusion support in the 1980s. From the 2000s the technology branched into a loosely regulated consumer wellness-mat industry that borrowed the medical pedigree.

  1. 1957Fukada and Yasuda report the piezoelectric effect of bone in Japan
  2. 1974Bassett, Pilla and Pawluk publish inductively coupled bone-repair results in Science
  3. 1979FDA clears non-invasive bone-growth stimulators for fracture nonunion
  4. 1980sPEMF adopted as an adjunct to spinal fusion in at-risk patients
  5. 2001Cochrane assessment finds insufficient evidence of clinical benefit in knee OA
  6. 2007Ivivi SofPulse cleared via 510(k) for post-operative pain and edema
  7. 2012Hug and Roosli review of whole-body PEMF devices judges the evidence insufficient
  8. 2017BioElectronics ActiPatch cleared OTC for knee OA and plantar fasciitis
  9. 2020ActiPatch OTC clearance expanded to musculoskeletal pain generally
  10. 2022Tong meta-analysis (11 RCTs) reports OA benefit but with very high heterogeneity
  11. 2026FDA final order reclassifies non-invasive bone-growth stimulators from Class III to Class II, effective May 18

At a glance

Bone nonunion
FDA-approved bone-growth stimulators since 1979 (Class III PMA)
Knee OA evidence
Mixed: some meta-analyses positive, older reviews null
Wellness mats
FDA-listed only, not approved; efficacy claims largely unproven
Hard limit
Contraindicated over pacemakers and other active implants

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about PEMF Therapy. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.

Sources